Insights

Innovative Therapies Miltenyi Biomedicine specializes in cutting-edge cell and gene therapies such as CAR T, CAR NK, and iPSC technologies, presenting opportunities to introduce complementary products or services that enhance or support their advanced therapeutic development process.

Recent Data Visibility The company's presentation of new clinical data at ASH 2025 indicates a focus on expanding clinical trial outcomes, suggesting potential collaboration or supply opportunities in clinical-stage research and diagnostics.

Growing Clinical Focus Recent hiring of a Clinical Development Medical Director and active participation in major hematology conferences highlight a strategic emphasis on clinical research, creating prospects for technical partners, CRO services, or clinical trial support solutions.

Revenue Range Opportunity With an annual revenue of $50M to $100M, Miltenyi Biomedicine presents a mid-market target for scalable solutions, including specialized lab instrumentation, reagents, or support services tailored for pharmaceutical and biotechnological R&D.

Industry Positioning As a company committed to addressing unmet medical needs in oncology and regenerative medicine within a competitive landscape, there is an opportunity to offer innovations in manufacturing, supply chain optimization, or regulatory consulting to support their growth trajectory.

Similar companies to Miltenyi Biomedicine

Miltenyi Biomedicine Tech Stack

Miltenyi Biomedicine uses 8 technology products and services including Usercentrics, Open Graph, Cloudflare, and more. Explore Miltenyi Biomedicine's tech stack below.

Usercentrics
Consent Management
Open Graph
Content Management System
Cloudflare
Content Management System
styled-components
Javascript Frameworks
Microsoft
Miscellaneous
MouseFlow
Web Analytics
Gatsby
Web Frameworks
Apache HTTP Server
Web Servers

Media & News

Miltenyi Biomedicine's Email Address Formats

Miltenyi Biomedicine uses at least 1 format(s):

Miltenyi Biomedicine Email Formats	Example	Percentage
First.Last@miltenyibiomedicine.com	John.Doe@miltenyibiomedicine.com	90%
FirstL@miltenyibiomedicine.com	JohnD@miltenyibiomedicine.com	8%
Fir.Last@miltenyibiomedicine.com	Joh.Doe@miltenyibiomedicine.com	1%
Last.First@miltenyibiomedicine.com	Doe.John@miltenyibiomedicine.com	1%

Frequently Asked Questions

What is Miltenyi Biomedicine's official website and social media links?

Miltenyi Biomedicine's official website is miltenyibiomedicine.com and has social profiles on LinkedIn.

What is Miltenyi Biomedicine's NAICS code?

Miltenyi Biomedicine's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Miltenyi Biomedicine have currently?

As of January 2026, Miltenyi Biomedicine has approximately 169 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Officer North America Biomedicine: S. L.Chief Medical Officer, Usa: A. W.Vp Clinical Development At Miltenyi Biomedicine: R. K.. Explore Miltenyi Biomedicine's employee directory with LeadIQ.

What industry does Miltenyi Biomedicine belong to?

Miltenyi Biomedicine operates in the Pharmaceutical Manufacturing industry.

What technology does Miltenyi Biomedicine use?

Miltenyi Biomedicine's tech stack includes UsercentricsOpen GraphCloudflarestyled-componentsMicrosoftMouseFlowGatsbyApache HTTP Server.

What is Miltenyi Biomedicine's email format?

Miltenyi Biomedicine's email format typically follows the pattern of First.Last@miltenyibiomedicine.com. Find more Miltenyi Biomedicine email formats with LeadIQ.

When was Miltenyi Biomedicine founded?

Miltenyi Biomedicine was founded in 2019.

Miltenyi Biomedicine

Q: How many employees does Miltenyi Biomedicine have currently?

Miltenyi Biomedicine has approximately 169 employees.

Q: What technology does Miltenyi Biomedicine use?

Miltenyi Biomedicine's tech stack includes X-XSS-Protection, Open Graph, Google Analytics, X-Content-Type-Options, Usercentrics.

Pharmaceutical ManufacturingNorth Rhine-westphalia, Germany51-200 Employees

Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. 
Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. 
For more information, please visit our website at www.miltenyibiomedicine.com.